Sensydia, a non-invasive cardiac diagnostic company, has been granted a $3 million Fast-Track Small Business award from the National Heart, Lung, and Blood Institute (NHLBI), a branch of the National Institutes of Health (NIH).
This non-dilutive funding will support the development and clinical testing of machine learning algorithms for their Cardiac Performance System (CPS). The CPS aims to facilitate earlier detection and therapy guidance for patients with heart failure and pulmonary hypertension.
The grant follows Sensydia's recent $8 million venture funding round and is divided into Phase I ($600,000) and Phase II ($2.4 million) segments.
Sensydia's CPS platform offers non-invasive cardiac performance assessment outside hospitals, potentially revolutionising heart failure therapy.
The system utilises proprietary waveform machine-learning techniques and has received FDA clearance for various measurements.
Click here to read the original news story.